According to FutureWise analysis the market for lentiviral vector in 2023 was US$ 176.8 million, and is expected to reach US$ 690 million by 2031 at a CAGR of 17.6%.

Lentiviral vectors (LV) are effective vehicles for gene transfer in mammalian cells due to their ability to stably express a gene of interest in both non-dividing and dividing cells. Pathogens known as lentiviruses affect both humans and animals and have protracted incubation times. The interval between the first infection and the onset of the first symptoms can be many months or even several years. To introduce genetic material into cells, molecular scientists typically use viral vectors. The operation can be carried out (in vitro) as well as In vivo (within a living creature) or in cell culture. For effective genome transfer inside the infected cells, viruses have developed specialised molecular pathways.

Over the past two decades, lentiviral vectors, which are derived from the human immunodeficiency virus, have been thoroughly studied and improved. Recent clinical trials have used third-generation, self-inactivating lentiviral vectors to insert genes into hematopoietic stem cells to treat primary immunodeficiencies and hemoglobinopathies. The development of gene-modified cell therapies, particularly T-cell therapies, has been greatly aided by lentiviral vectors. Examples of T cell treatments that are currently commercially accessible for distribution after successfully getting EMA and FDA authorisation for the treatment of blood malignancies include tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta) and, most recently brexucabtagene autoleucel (Tecartus). The therapeutic chimeric antigen receptor (CAR) is transduced into T cells in all three treatments using retroviral vectors.

FutureWise Market Research has published a report that provides an insightful analysis of lentiviral vector market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/healthcare-market-research/Lentiviral-Vector-Market/14631

Lentiviral Vector Market Segmentation:

By Component

• Lentiviral Promoter
  • Lentivirus Promoter Vectors
  • Lentivirus Promoterless Vectors
• Lentivirus Packaging Systems
• Lentiviral Fusion Tags
• Others

By Type

• Product
  • Human Immunodeficiency Virus (Hiv)
  • Feline Immunodeficiency Virus (Fiv)
  • Equine Infectious Anemia Virus (Eiav)
• Services

By Generation

• 4th Generation
• 3rd Generation
• 2nd Generation
• 1st Generation

By Workflow

• Upstream Processing
  • Vector Amplification and Expansion
  • Vector Recovery/ Harvesting
• Downstream Processing
  • Purification
  • Fill-finish

By Delivery Method

• In-vivo
• Ex-vivo

By Disease Indication

• Cancer
• Genetic Disorders
  • B-thalessemia
  • X-linked Adreno Leukodystrophy
  • Metachromatic Leukodystrophy
  • Wiskott-aldrich Syndrome
  • Others
• Infectious Diseases
  • Hiv
  • Others
• Veterinary Diseases
• Others

By Application

• Gene Therapy
  • Recombinant Protein Expression
  • Functional Assays
  • In Vitro Transcription
  • Protein Characterization
  • Others
• Vaccinology

By End Users

• Academic/ Research Institutes
• Pharmaceutical Companies
• Contract Development and Manufacturing Organizations
• Biotechnology Companies
• Contract Research Organizations

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in the Lentiviral Vector Market:

• Oxford Biomedica
• Thermo Fisher Scientific Inc.
• Merck KgaA
• Lonza
• Cytiva
• Applied Biological Materials Inc.
• Batavia Biosciences B.V.
• Bluebird Bio, Inc.
• Cell Biolabs, Inc
• Creative Biolabs
• Cobra Biologics Limited
• Finvector Oy
• Fujifim Diosynth Biotechnologies (A Subsidiary Of Fujifilm Holdings Corporation)
• Genemedi
• Origene Technologies, Inc..
• Sino Biological, Inc.
• Sirion-biotech GmbH
• System Biosciences, LLC
• Takara Bio Inc.
• Waisman Biomanufacturing

Buy now the latest version of this report:
https://www.futurewiseresearch.com/contact.aspx?rpt=14631%20&type=discount

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Lentiviral Vector Market By Component, By Type, By Generation, By Workflow, By Delivery Method, By Disease Indication, By Application, By End Users and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]

FutureWise Research

Contact Person: Vinay Thaploo.

Email: [email protected]

Contact Number: Asia: +91 8605575209 | USA: +1 3477094931

Website: www.futurewiseresearch.com